Handelsavisen
prelaunch
Companies Healthcare 4599.T
45
4599.T Tokyo Stock Exchange Pharmaceuticals

4599.T

¥285,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
17,9B JPY
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
-26,4 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development and commercialization of innovative drug therapies.

Business. 4599.T is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Detailed information regarding its operating segments, headquarters location, and primary stock exchange listing is not available in the provided data. Consequently, the company is described at the industry level without specific geographic or segmental breakdowns.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target700,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
700,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-26,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4599.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4599.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    4599.T is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Detailed information regarding its operating segments, headquarters location, and primary stock exchange listing is not available in the provided data. Consequently, the company is described at the industry level without specific geographic or segmental breakdowns.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 83.35, indicating a significant excess of current assets over current liabilities. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce the company's financial stability. However, the company's operating cash flow is negative at -1.41 billion JPY, and free cash flow is also negative at -1.92 billion JPY, suggesting ongoing operational challenges.

    Profitability metrics are negative, with a return on equity of -26.38% and a return on assets of -25.66%, both significantly below industry norms. The company reported a net loss of 1.93 billion JPY, and operating income was also negative at 1.93 billion JPY, indicating a lack of profitability. The price-to-book ratio of 2.47 suggests that the market is valuing the company at a premium to its book value, despite the negative earnings.

    The company's revenue is reported as 0.0 JPY, which may indicate a reporting anomaly or a strategic shift in operations. There is no disclosed segment or geographic breakdown provided in the available data, making it difficult to assess revenue concentration or diversification. The absence of detailed segment data limits the ability to evaluate the company's exposure to different markets or product lines.

    The company's growth trajectory is unclear due to the lack of historical revenue data and the absence of forward-looking guidance in the provided information. Analysts have assigned a mean price target of 700.00 JPY, significantly higher than the current market price of 288.0 JPY, suggesting a potential for substantial upside. However, the mean recommendation of 2.00 (Buy) is tempered by the absence of strong-buy ratings and the presence of only one buy recommendation.

    The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is free of long-term debt, and the dilution potential is low, as the basic and diluted shares outstanding are identical. However, the negative operating and free cash flows suggest potential liquidity pressures in the future.

    Recent events and filings do not provide specific details on the company's operations or strategic direction. The absence of detailed transcripts or recent filings limits the ability to assess the company's management commentary or strategic initiatives. The company's capital expenditure of -43.86 million JPY indicates a reduction in investment in physical assets.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 83.35 and no long-term debt.
    • Profitability is negative, with a return on equity of -26.38% and a return on assets of -25.66%.
    • Analysts have assigned a mean price target of 700.00 JPY, significantly higher than the current market price of 288.0 JPY.
    • The company's capital structure is free of long-term debt, and the dilution potential is low.
    • The absence of detailed segment and geographic data limits the ability to assess revenue concentration and diversification.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥285,00
    Market cap
    ¥18.05B
    Enterprise value
    ¥11.06B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    2.5x
    P / Tangible book
    2.5x
    Tangible book
    ¥7.31B
    Net cash
    ¥6.99B
    Current ratio
    83.3
    Debt / equity
    0.0
    ROA
    -25.7%
    ROE
    -26.4%
    Cash conversion
    73.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target¥700,00 · Median ¥700,00
    Low ¥700,00High ¥700,00

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥700,00
    Mean¥700,00
    Median¥700,00
    High¥700,00
    Spot¥285,00
    +145.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-26,4 %Bottom quartile
    D/E0,00Above P75
    Cash Conv0,73Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • 4599.T Market data — financials · 2026-05-26
    • StemRIM Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4599.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage